Anti-FcRL5 CAR-T Cell Therapy(Xuzhou Medical University)

N/A

Report date: 2024/01/10 20:11:04

Base Information

Drug NameAnti-FcRL5 CAR-T Cell Therapy(Xuzhou Medical University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsFc receptor-like protein 5 inhibitors

TargetsFc receptor-like protein 5

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesXuzhou Medical University (Xzmu)

China Registration ClassN/A

Develop Information

Active CompaniesXuzhou Medical University (Xzmu)

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A